Metabolic consequences of gender‐affirming hormone therapy in transgender adult persons

As more individuals seek to align their physical characteristics with gender identity, transgender health care is a growing medical field which no longer the remit of few selected clinicians. Gender-affirming hormone therapy (GAHT) mainstay treatment in reassignment and its medium- long-term metabolic sequelae are gradually emerging. Although hampered by scarcity prospective controlled studies involving large diverse cohorts, evidence suggests potential adverse impact for at least some cardiovascular disease (CVD) risk factors. If left unmanaged, this could manifest higher CVD events rate group. Increased vigilance awareness among professionals about consequential risks GAHT important proactive mitigation this. Copyright © 2023 John Wiley & Sons.